| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abe0b8deaaba805e203682c662245168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2512ae14bef068f3d09c32dbec2586fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6359faead2c74c81173d22d21402708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0cbaaf7094d0b513aff52bba5bcd08b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f28306adab6953d083eb8b65acbbad0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5f465cf97942eaf80cc8946cc4c8108 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2014-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_827a0c6aca4a8e2c352a65247be95146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8723918d6bc04a97cfa6aaa85fcfa3cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7523bf87e60a60048271f62685da33c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aac2bb60d954a81368c729f01041d70e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_196762aa0dbaa3ce3ed03bf54858a057 |
| publicationDate |
2015-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2951589-A1 |
| titleOfInvention |
Methods for predicting and preventing metastasis in triple negative breast cancers |
| abstract |
In particular the present invention relates to a method for predicting the risk of relapse and distant metastasis in a patient suffering from a triple negative breast cancer comprising the step of i) determining the level of soluble CD95L in a blood sample obtained from the patient ii) comparing the level determined at step i) with a predetermined reference value and iii) concluding that the patient will exhibit an increased risk of relapse and distant metastasis when the level determined at step i) is higher than the predetermined reference value or concluding that the patient will exhibit a decreased risk of relapse and distant metastasis when the level determined at step i) is lower than the predetermined reference value. The present invention also relates to a method of preventing metastases in a subject suffering from triple negative breast cancer comprising the steps consisting of i) predicting the risk of relapse and distant metastasis by the method according to the invention and ii) administering the subject with a therapeutically effective amount of a CD95 antagonist when it is concluded at step i) that the subject will exhibit an increased risk of relapse and distant metastasis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2648523-C1 |
| priorityDate |
2013-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |